Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

24.1%

13 terminated/withdrawn out of 54 trials

Success Rate

59.4%

-27.2% vs industry average

Late-Stage Pipeline

11%

6 trials in Phase 3/4

Results Transparency

195%

37 of 19 completed trials have results

Key Signals

5 recruiting37 with results7 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

42(79.2%)

Phase 3

6(11.3%)

Phase 1

3(5.7%)

N/A

2(3.8%)

53Total

Phase 2(42)

Phase 3(6)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials

NCT04626791Phase 2Active Not Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Role: lead

NCT05194293Phase 2Active Not Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Role: lead

NCT03012100Phase 2Active Not Recruiting

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Role: lead

NCT04879368Phase 3Completed

RegoNivo vs Standard of Care Chemotherapy in AGOC

Role: collaborator

NCT04042831Phase 2Active Not Recruiting

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Role: lead

NCT05199285Phase 2Terminated

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Role: lead

NCT03233347Phase 2Active Not Recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Role: lead

NCT05246670Phase 2Active Not Recruiting

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Role: lead

NCT05168163Phase 2Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Role: lead

NCT02758717Phase 2Active Not Recruiting

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Role: lead

NCT02973997Phase 2Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Role: lead

NCT03765736Terminated

Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Role: lead

NCT02368886Phase 2Completed

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Role: lead

NCT03080883Phase 3Completed

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Role: lead

NCT03043313Phase 2Completed

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Role: collaborator

NCT06160206Phase 2Recruiting

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Role: lead

NCT05910801Phase 2Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Role: lead

NCT04117945Phase 2Active Not Recruiting

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Role: lead

NCT06238648Phase 2Recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Role: lead

NCT04756401Phase 2Active Not Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Role: lead